Capsida Biotherapeutics

US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option for the first neurodegenerative disease program as part of their collaboration formed in 2023. As a result, Capsida will receive a USD 40 million license payment and is eligible for additional milestones and royalties. Results…